

In collaboration with The Oxford University Clinical Research Unit, Vietnam



MONDAY 04 NOVEMBER 2024

Venue: Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam

Time Activity

14.00 Tour of OUCRU Laboratory Facilities – Limited places: Confirmed Names Only

The programme is subject to change















TUESDAY 05 NOVEMBER 2024 Venue – Sheraton Hotel, Ho Chi Minh City, Vietnam

Гime	Activity
08.30	Registration
09.00	Welcome - Network Information Professor Cal MacLennan, Director of BactiVac & Professor Adam Cunningham, Co-Director of BactiVac, UK
09.15	BactiVac Network - Opening Address Professor Peter Borriello, Trustee of Safe Medicines for Animals - regulatory training (SMArt), UK
09.30	Oxford University Clinical Research Unit - Opening Address Professor Guy Thwaites, Director, Oxford University Clinical Research Unit, Vietnam
09.45	Vaccines to Prevent Antimicrobial Resistance – Data from Three Phase 3 Typhoid Conjugate Vaccine Trials Dr James E. Meiring, Senior Clinical Lecturer, University of Liverpool and Malawi Liverpool Wellcome Trust Programme, UK/Malawi
10.15	Development and Qualification of Immunoassays for Shigella Vaccines Dr Paul W. Rhyne, Bioassay Lead, Gates Medical Research Institute, USA
10.45	Speed Networking Session
12.30	Lunch
13.30	Technologies Available for Bacterial Vaccines Dr Francesca Micoli, Senior Project Leader and Director of the Innovation Academy at GSK Vaccine Institute for Global Health, Italy
14.00	MRNA as a Platform for Bacterial Vaccines Dr Obadiah Plante, Sr. Director, Bacteriology, Infectious Disease Research, Moderna, USA
14.30	Combination Bacterial Vaccines Professor Dr Annelies Wilder-Smith, Team Lead for Vaccine Development, World Health Organisation, Switzerland
15.00	Refreshments
15.30	Vaccine Clinical Trials, Recent Advancements, Challenges & Opportunities Dr Tarun Saluja, Head of Clinical Development, International Vaccine Institute, South Korea
16.00	Oral Paratyphoid Vaccine Study in the Human Challenge Model Professor Sir Andrew Pollard, Director of the Oxford Vaccine Group at the University of Oxford and a Consultant Paediatrician at the Oxford Children's Hospital, UK
16.30	Klebsiella Pneumoniae in Vietnam: The Urgent Need for a Vaccine Dr Duy Pham, Head of Molecular Epidemiology Group, Oxford University Clinical Research Unit, Vietnam
17.00	Bangladesh Vaccine Therapeutics Diagnostics and Manufacturing and Regulatory Strengthening Dr Dinesh Arora, Principal Health Specialist, Asian Development Bank, Philippines
17.30	Close of day programme
19.00	Conference Dinner – The Sheraton Hotel













WEDNESDAY 06 NOVEMBER 2024 Venue – Sheraton Hotel, Ho Chi Minh City, Vietnam Time Activity 08.30 DCVMN in Pursuit for Excellence: A Journey of Innovations, Development, Manufacturing and Delivery of **Bacterial Vaccines** Mr Rajinder Kumar Suri, CEO, DCVMN International, India 09.00 **Biological E's Longstanding Commitment of Bacterial Vaccine Development** Dr Nupur Sengupta, General Manager, Global Alliance Management, Bio E-Vaccines, India 09.30 The Group B Streptococcal Vaccine Pipeline Professor Kirsty Le Doare, Professor of Vaccinology and Immunology, St. George's. University of London, UK 10.00 Standardization of Immune Assays for Characterizing Immune Responses to GBS Vaccines in Clinical Studies Dr Rama Raghunandan, Scientific Director, PATH, USA 10.30 Refreshments 11.00 Encouraging the Use of Biological Products and Vaccines to Replace Antibiotics to Meet the Export Strategy of the **Ministry of Agriculture and Rural Development** Dr Dang Thi Thanh SON, Head of Veterinary Hygiene Department, National Institute for Veterinary Research (NIVR), Vietnam 11.30 **Reduction of Antibiotic Use in Tilapia Farming** Associate Professor Nguyen Ngoc Phuoc, Senior Lecturer, Faculty of Fishery, University of Agriculture and Forestry, Hue University, Vietnam 12.00 Streptococcus suis Infection in Human: A New Insight from Whole Genome Sequence Study Associate Professor Ngo Thi Hoa, Head of Zoonoses Group, Oxford University Clinical Research Unit, Vietnam 12.30 Lunch 13.30 Toward a multivalent synthetic oligosaccharide-based conjugate vaccine against Shigella: clinical findings from a monovalent prototype in Kenyan infants Dr Laurence A. Mulard, Research Director, INSTITUT PASTEUR, France 14.00 **BactiVac Network Opportunities**

Dr Jo Dean, Operations Manager, BactiVac Network, UK

Oral Presentations from Selected Poster Abstracts

The programme is subject to change







See Appendix 1

Poster Abstract Viewing

Close of day programme

14.30

16.00

18.00











THURSDAY 07 NOVEMBER 2024 Venue – Sheraton Hotel, Ho Chi Minh City, Vietnam

Time	Activity
09.00	The Challenge of Developing Vaccines against Human Adapted Pathogens Professor Christoph Tang, Professor of Cellular Pathology, Sir William Dunn School of Pathology, UK
09.30	Clinical Trials in Asia – Opportunities and Challenges Dr Evelyne Kestelyn, Head of the Clinical Trials Unit, Oxford University Clinical Research Unit, Vietnam
10.00	The Role of the Social Structure in Vaccine Hesitancy Dr Ha Nguyen Thanh, Postdoctoral Researcher, Oxford University Clinical Research Unit, Vietnam
10.30	Refreshments
11.00	The Clinical Challenge of Acinetobacter baumannii and Potential New Therapeutic Approaches Professor Jeremy Brown, Professor of Respiratory Infection, University College London, UK
11.30	K-Vax: The Universal Vaccine for Prevention of Diseases by Klebsiella Pneumoniae Dr Aída Alonso-del Valle, Vaccine Development Manager, Vaxdyn, Spain
12.00	Perspective on the Success of Bacterial Vaccine Development and Manufacture in Asia Dr Jerome Kim, Director General of the International Vaccine Institute, South Korea
12.30	Lunch
14.00	Translational Workshop by Hilleman Laboratories What Does it Take to Move a Vaccine Through the First 'Valley of Death?'
	Welcome & Opening Dr Alain Bouckenooghe, Head of Research &Development, Hilleman Laboratories, Singapore
14.05	Vaccine development: From Lab to Clinic Dr Pei-Yin Lim, Manager, Preclinical R&D, Hilleman Laboratories, Singapore
14.30	Building a Business Case Dr N Erlyani Abd Hamid, Assistant Director, Business Strategy & Programme Management, Hilleman Laboratories, Singapore
15.00	Rapid Approach to Vaccine Development with Case Study Kay Hunsberger, Executive Director, Merck Sharp & Dohme Inc., USA
15.30	Refreshments
16.00	Panel Session Q&A Session

Annual Network Meeting Closing Address

Professor Cal MacLennan Director of Bactive

 $\textit{Professor Cal MacLennan, Director of BactiVac \& \textit{Professor Adam Cunningham, Co-Director of BactiVac, UK} \\$

The programme is subject to change





17.00











APPENDIX 1

Venue - Sheraton Hotel, Ho Chi Minh City, Vietnam

WEDNESDAY 06 NOVEMBER 2024

Oral Presentations from Selected Poster Abstracts

- 14.30 Turbo: an adjuvant for bacterial polysaccharide vaccines

 Dr Kishore R. Alugupalli, Chief Executive Officer, TurboVax Inc., USA
- 14.45 Safety and immunogenicity of a 4-component GMMA-based Shigella vaccine in healthy European adults: Stage 1 of a randomized, controlled phase I/II clinical trial

 Dr Ashwani Kumar Arora, Head Clinical Development & Regulatory Affairs, GSK Vaccines for Global Health, Italy
 - Dr Ashwani Kumar Arora, Head Clinical Development & Regulatory Affairs, GSK Vaccines for Global Health, Italy
- 15.00 Exploring the role of pneumococcal conjugate vaccine (PCV)-13 and its mechanism against *Streptococcus* pneumoniae

 Dr Gift Chiwala, Postdoctoral Research Associate, Malawi Liverpool Wellcome Programme, Malawi
- 15.15 Comparative analysis of gonococcal antibody levels and function in sera from mice immunised with candidate native Outer Membrane Vesicle (nOMV) gonococcal vaccines and from patients convalescing from gonorrhoea *Ms Ilaria Onofrio, DPhil student, Jenner Institute, University of Oxford, UK*
- 15.30 Live vector-based multivalent vaccine approach against cecal colonization of *Campylobacter jejuni* in commercial chickens

 Dr Amirul Islam Mallick, Associate Professor, Indian Institute of Science Education and Research Kolkata, India
- 15.45 Preliminary analysis and outcomes from a first-in-human Nontyphoidal *Salmonella* controlled human infection model

Dr Christopher Smith, Clinical Research Fellow, Imperial College London, UK

The programme is subject to change











